PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) today announced a new agreement to expand access to Reyataz ® (atazanavir sulfate). The immunity-from-suit agreement signed ...
Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer After Moderately Emetogenic Chemotherapy Chemotherapy-naive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback